Sight Sciences announces large-scale MIGS data

Sight Sciences announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery, MIGS, technologies, which were recently presented at the 41st Congress of the European Society of Cataract and Refractive Surgeons, ESCRS, in Vienna, Austria. Using the American Academy of Ophthalmology IRIS Registry, the largest specialty society clinical data registry in all of medicine and the first comprehensive eye disease clinical registry in the United States, this large-scale MIGS study evaluated long-term 2-year post-surgical outcomes among patients with glaucoma treated with the three most commonly used FDA approved/cleared ab interno MIGS devices in the U.S. combined with cataract surgery, as well as for cataract surgery alone. The primary treatment goal for the high baseline IOP group was IOP reduction, with a secondary goal to reduce medication burden. The primary treatment goal for the low baseline IOP group was to reduce medication burden. Clinical Outcomes: At 24 months, high baseline IOP patients who received the TCOR procedure using OMNI technology had: the greatest numerical reduction in IOP, and the greatest numerical reduction in medication use. At 24 months, low baseline IOP patients who received the TCOR procedure using OMNI technology had: the greatest numerical reduction in IOP, and a statistically significant greater mean medication reduction compared to all other treatment groups at 24 months